Skip Navigation Links
Review of Sinopharm (1099.HK)
19 Dec 2022 (219 views)  

I hold 30,000 shares in Sinopharm. My average cost is HK$21.2. The current price is $20.3. I have a loss of SGD $5,500 on this holding. 

Sinopharm hit a low of $14.6 on 7 Oct. It has recovered 40% from this bottom.

The current price earning ratio is 6.77 times and the dividend yield is 4.2%. Sinopharm is expected to report better profit for the current financial year. 

With the surge in covid infection in China, following the recent relaxation of covid restriction, I expect an increase demand for Sinopharm's products.

I will buy another 15,000 shares. 

Note - I am sharing my personal investment decision. Do not treat it as " investment advice". 

Tan Kin Lian
 


Review of Sinopharm (1099.HK)
[Back] [Print]


I hold 30,000 shares in Sinopharm. My average cost is HK$21.2. The current price is $20.3. I have a loss of SGD $5,500 on this holding. 

Sinopharm hit a low of $14.6 on 7 Oct. It has recovered 40% from this bottom.

The current price earning ratio is 6.77 times and the dividend yield is 4.2%. Sinopharm is expected to report better profit for the current financial year. 

With the surge in covid infection in China, following the recent relaxation of covid restriction, I expect an increase demand for Sinopharm's products.

I will buy another 15,000 shares. 

Note - I am sharing my personal investment decision. Do not treat it as " investment advice". 

Tan Kin Lian